Gilead execs tick off its three top areas of M&A interest

Now that Gilead ($GILD) faces increased competition for its goliath share of the U.S. hep C market with Merck's ($MRK) fresh arrival on the scene, the Big Biotech is keeping a mental checklist of potential new collaborations and acquisitions that might help rev up some added excitement for the company's shares. In its review of annual numbers on Tuesday night, Gilead's John Milligan--soon to be CEO--cited three key areas of interest: oncology, inflammatory diseases and liver diseases. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.